NAV

Cimetropium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Cimetropium
DrugBank Accession Number
DB09271
Background

Cimetropium is a semi-synthetic belladonna alkaloid and derivative of scopolamine. It is a potent antimuscarinic and an effective antispasmodic drug. It is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity. It has never been approved for use in the U.S. or Canada.

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Similar Structures
Weight
Average: 358.457
Monoisotopic: 358.201284806
Chemical Formula
C21H28NO4
Synonyms
  • Cimetropium cation
  • Cimetropium ion
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcetylcholineAcetylcholine may decrease the anticholinergic activities of Cimetropium.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Cimetropium.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cimetropium.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cimetropium.
Anisotropine methylbromideThe risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Cimetropium.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Cimetropium bromide0C7M5WE60Q51598-60-8WDURTRGFUGAJHA-GSWUYBTGSA-M

Categories

ATC Codes
A03BB05 — Cimetropium bromide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Beta hydroxy acids and derivatives
Direct Parent
Beta hydroxy acids and derivatives
Alternative Parents
Benzene and substituted derivatives / Piperidines / Morpholines / N-alkylpyrrolidines / Tetraalkylammonium salts / Carboxylic acid esters / Azacyclic compounds / Oxacyclic compounds / Dialkyl ethers / Epoxides
show 7 more
Substituents
Alcohol / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl ether
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
1N3H74AYTK
CAS number
150521-16-7
InChI Key
QVVOZYKELHAIPX-WVHCHWADSA-N
InChI
InChI=1S/C21H28NO4/c1-22(11-13-7-8-13)17-9-15(10-18(22)20-19(17)26-20)25-21(24)16(12-23)14-5-3-2-4-6-14/h2-6,13,15-20,23H,7-12H2,1H3/q+1/t15-,16-,17-,18+,19-,20+,22?/m1/s1
IUPAC Name
(1R,2R,4S,5S,7S)-9-(cyclopropylmethyl)-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium
SMILES
[H][C@](CO)(C(=O)O[C@@]1([H])C[C@@]2([H])[C@]3([H])O[C@]3([H])[C@@]([H])(C1)[N+]2(C)CC1CC1)C1=CC=CC=C1

References

General References
  1. Scarpignato C, Bianchi Porro G: Cimetropium bromide, a new antispasmodic compound: pharmacology and therapeutic perspectives. Int J Clin Pharmacol Res. 1985;5(6):467-77. [Article]
KEGG Drug
D07099
PubChem Compound
20054871
PubChem Substance
310265166
ChemSpider
28529144
ChEBI
135516
ChEMBL
CHEMBL2110773
ZINC
ZINC000100014304
Wikipedia
Cimetropium_bromide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Unknown StatusDiagnosticColonoscopy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution
Solution / dropsOral
Suppository
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00244 mg/mLALOGPS
logP0.45ALOGPS
logP-2.5Chemaxon
logS-5.2ALOGPS
pKa (Strongest Acidic)15.15Chemaxon
pKa (Strongest Basic)-2.7Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area59.06 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity107.58 m3·mol-1Chemaxon
Polarizability38.5 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-02mi-0910000000-571e9885271335a890cf
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-178.62227
predicted
DeepCCS 1.0 (2019)
[M+H]+180.44716
predicted
DeepCCS 1.0 (2019)
[M+Na]+186.1455
predicted
DeepCCS 1.0 (2019)

Drug created at October 28, 2015 19:38 / Updated at June 12, 2020 16:52